Quality assuring "Plan of the day" selection in a multicentre adaptive bladder trial: Implementation of a pre-accrual IGRT guidance and assessment module.
Adaptive
Bladder
IGRT
Radiotherapy
Trial QA
Journal
Clinical and translational radiation oncology
ISSN: 2405-6308
Titre abrégé: Clin Transl Radiat Oncol
Pays: Ireland
ID NLM: 101713416
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
07
01
2019
revised:
11
07
2019
accepted:
22
07
2019
entrez:
8
8
2019
pubmed:
8
8
2019
medline:
8
8
2019
Statut:
epublish
Résumé
Hypofractionated bladder RT with or without image guided adaptive planning (HYBRID) is a multicentre clinical trial investigating "Plan of the Day" (PoD) adaptive radiotherapy for bladder cancer. To ensure correct PoD selection a pre-accrual guidance and assessment module was developed as part of an image guided radiotherapy quality assurance (IGRT QA) credentialing programme. This study aimed to evaluate its feasibility and effectiveness across multiple recruiting centres. Individuals from participating centres remotely accessed an image database in order to complete the PoD module. An assessment score of ≥83% was required in order to receive QA approval. A questionnaire was used to gather user feedback on the module. PoD decisions for the first patient at each recruiting centre were retrospectively reviewed for protocol adherence. 71 radiation therapists (RTTs) from 10 centres completed the PoD module. The median assessment score was 92% (Range: 58-100%) with 79% of RTTs passing the assessment on first attempt. All questionnaire respondents reported that the PoD module prepared them for plan selection. In 51/60 of on-trial treatments reviewed, the PoD selected by the centre agreed with QA reviewers. The PoD QA module was successfully implemented in a multicentre trial and enabled pre-accrual assessment of protocol understanding. This increased operator confidence and resulted in appropriate PoD selection on-trial.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Hypofractionated bladder RT with or without image guided adaptive planning (HYBRID) is a multicentre clinical trial investigating "Plan of the Day" (PoD) adaptive radiotherapy for bladder cancer. To ensure correct PoD selection a pre-accrual guidance and assessment module was developed as part of an image guided radiotherapy quality assurance (IGRT QA) credentialing programme. This study aimed to evaluate its feasibility and effectiveness across multiple recruiting centres.
MATERIALS AND METHODS
METHODS
Individuals from participating centres remotely accessed an image database in order to complete the PoD module. An assessment score of ≥83% was required in order to receive QA approval. A questionnaire was used to gather user feedback on the module. PoD decisions for the first patient at each recruiting centre were retrospectively reviewed for protocol adherence.
RESULTS
RESULTS
71 radiation therapists (RTTs) from 10 centres completed the PoD module. The median assessment score was 92% (Range: 58-100%) with 79% of RTTs passing the assessment on first attempt. All questionnaire respondents reported that the PoD module prepared them for plan selection. In 51/60 of on-trial treatments reviewed, the PoD selected by the centre agreed with QA reviewers.
CONCLUSIONS
CONCLUSIONS
The PoD QA module was successfully implemented in a multicentre trial and enabled pre-accrual assessment of protocol understanding. This increased operator confidence and resulted in appropriate PoD selection on-trial.
Identifiants
pubmed: 31388568
doi: 10.1016/j.ctro.2019.07.006
pii: S2405-6308(19)30002-3
pmc: PMC6675972
doi:
Types de publication
Journal Article
Langues
eng
Pagination
27-32Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Tech Innov Patient Support Radiat Oncol. 2018 Jan 16;5:1-2
pubmed: 32095567
Radiother Oncol. 2013 Oct;109(1):165-9
pubmed: 23182055
Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):705-12
pubmed: 20472358
Radiother Oncol. 2012 Jun;103(3):293-8
pubmed: 22483676
Clin Oncol (R Coll Radiol). 2013 Sep;25(9):549-56
pubmed: 23880296
J Med Phys. 2013 Apr;38(2):59-66
pubmed: 23776308
J Med Imaging Radiat Sci. 2017 Jun;48(2):199-206
pubmed: 31047369
Radiother Oncol. 2011 Jul;100(1):150-6
pubmed: 21722980
Clin Oncol (R Coll Radiol). 2013 Sep;25(9):546-8
pubmed: 23796918
Acta Oncol. 2018 May;57(5):566-573
pubmed: 29299945
Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1576-81
pubmed: 21074334
Br J Radiol. 2015 Apr;88(1048):20140690
pubmed: 25564753
Front Oncol. 2013 Mar 15;3:31
pubmed: 23508883
Acta Oncol. 2014 Aug;53(8):997-1004
pubmed: 24957559
Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):305-12
pubmed: 21236596